132 related articles for article (PubMed ID: 20948271)
21. Octreotide improved the quality of life in a child with malignant bowel obstruction caused by peritoneal dissemination of colon cancer.
Watanabe H; Inoue Y; Uchida K; Okugawa Y; Hiro J; Ojima E; Kobayashi M; Miki C; Kusunoki M
J Pediatr Surg; 2007 Jan; 42(1):259-60. PubMed ID: 17208578
[TBL] [Abstract][Full Text] [Related]
22. [A case of successful treatment using octreotide acetate for occlusive ileus in terminal stage cancer].
Yoshioka S; Tsujie M; Ebisui C; Okubo K; Akitake H; Otsuka M; Maekawa T; Hama N; Kashiwazaki M; Taniguchi M; Konishi M; Fujimoto T
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2266-8. PubMed ID: 20037391
[TBL] [Abstract][Full Text] [Related]
23. [Effect of octreotide on intragastric pH in patients with duodenal ulcer bleeding].
Nie Y; Li Y; Sha W; Dai S; She Q; Wu H
Zhonghua Yi Xue Za Zhi; 2001 May; 81(9):520-2. PubMed ID: 11809113
[TBL] [Abstract][Full Text] [Related]
24. Effects of a somatostatin analogue in occult gastrointestinal bleeding: a case report.
Tamagno G; Mioni R; De Carlo E; Maffei P; Rubello D; Sicolo N
Dig Liver Dis; 2004 Dec; 36(12):843-6. PubMed ID: 15646433
[TBL] [Abstract][Full Text] [Related]
25. Randomised clinical trial investigating the effects of combined administration of octreotide and methylglucamine diatrizoate in the older persons with adhesive small bowel obstruction.
Zhang Y; Gao Y; Ma Q; Dang C; Wei W; De Antoni F; Rocci R; Chen W
Dig Liver Dis; 2006 Mar; 38(3):188-94. PubMed ID: 16311083
[TBL] [Abstract][Full Text] [Related]
26. Safety of subcutaneous octreotide in patients with sulfonylurea-induced hypoglycemia and congestive heart failure.
Vallurupalli S
Ann Pharmacother; 2010 Feb; 44(2):387-90. PubMed ID: 20118140
[TBL] [Abstract][Full Text] [Related]
27. The use of octreotide in bowel obstruction.
Mercadante S
Palliat Med; 1993; 7(1):78. PubMed ID: 8287204
[No Abstract] [Full Text] [Related]
28. Octreotide acetate administration for malignant bowel obstruction induces severe bradycardia in patients with terminal stage cancer: two case reports.
Kubota K; Hasumi Y; Numata A; Tukazaki T; Horie K; Hashimoto K; Yokota H
J Palliat Med; 2013 Jun; 16(6):596-7. PubMed ID: 23600413
[No Abstract] [Full Text] [Related]
29. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
Angeli P; Volpin R; Gerunda G; Craighero R; Roner P; Merenda R; Amodio P; Sticca A; Caregaro L; Maffei-Faccioli A; Gatta A
Hepatology; 1999 Jun; 29(6):1690-7. PubMed ID: 10347109
[TBL] [Abstract][Full Text] [Related]
30. Octreotide acetate-steroid combination therapy for malignant gastrointestinal obstruction.
Murakami H; Matsumoto H; Nakamura M; Hirai T; Yamaguchi Y
Anticancer Res; 2013 Dec; 33(12):5557-60. PubMed ID: 24324097
[TBL] [Abstract][Full Text] [Related]
31. Octreotide may prevent definitive intestinal obstruction.
Mercadante S; Kargar J; Nicolosi G
J Pain Symptom Manage; 1997 Jun; 13(6):352-5. PubMed ID: 9204656
[TBL] [Abstract][Full Text] [Related]
32. Octreotide (SMS 201-995) for hematopoietic support-dependent high-dose chemotherapy (HSD-HDC)-related diarrhoea: dose finding study and evaluation of efficacy.
Wasserman E; Hidalgo M; Hornedo J; Cortés-Funes H
Bone Marrow Transplant; 1997 Nov; 20(9):711-4. PubMed ID: 9384471
[TBL] [Abstract][Full Text] [Related]
33. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction.
Mercadante S; Ripamonti C; Casuccio A; Zecca E; Groff L
Support Care Cancer; 2000 May; 8(3):188-91. PubMed ID: 10789958
[TBL] [Abstract][Full Text] [Related]
34. Octreotide in malignant intestinal obstruction.
Pandha HS; Waxman J
Anticancer Drugs; 1996 Jan; 7 Suppl 1():5-10. PubMed ID: 8822079
[TBL] [Abstract][Full Text] [Related]
35. The role of octreotide on renal function in patients with advanced cirrhosis.
Fierbinţeanu-Braticevici C; Udeanu M; Usvat R; Andronescu D
Rom J Intern Med; 2004; 42(1):173-81. PubMed ID: 15529607
[TBL] [Abstract][Full Text] [Related]
36. An unusual case of malignant gastro-intestinal obstruction in advanced cervical cancer.
Lübbe AS; Stange JH
J Cancer Res Clin Oncol; 2002 Mar; 128(3):171-2. PubMed ID: 11935305
[No Abstract] [Full Text] [Related]
37. SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction.
Laval G; Rousselot H; Toussaint-Martel S; Mayer F; Terrebonne E; François E; Brixi H; Nguyen T; Bourdeix I; Bisot-Locard S; Zelek L;
Bull Cancer; 2012 Feb; 99(2):E1-9. PubMed ID: 22265994
[TBL] [Abstract][Full Text] [Related]
38. Hepatic portal venous gas: a rare complication of malignant bowel obstruction during the administration of octreotide.
Maeda I; Tsuneto S; Yasui Y; Ueda Y; Kimura T
J Pain Symptom Manage; 2014 Feb; 47(2):e2-5. PubMed ID: 24388125
[No Abstract] [Full Text] [Related]
39. Intestinal obstruction.
Baines MJ
Cancer Surv; 1994; 21():147-56. PubMed ID: 8564990
[TBL] [Abstract][Full Text] [Related]
40. Palliation of malignant intestinal obstruction using octreotide.
Khoo D; Hall E; Motson R; Riley J; Denman K; Waxman J
Eur J Cancer; 1994; 30A(1):28-30. PubMed ID: 7511400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
